Head-To-Head Comparison: Bioventus (NASDAQ:BVS) vs. Nanovibronix (NASDAQ:FEED)

Nanovibronix (NASDAQ:FEED) and Bioventus (NASDAQ:BVS) are both small-cap manufacturing companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Valuation & Earnings

This table compares Nanovibronix and Bioventus”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.56 million	1.20	-$3.70 million	($41.74)	-0.07
Bioventus	$573.28 million	1.19	-$33.54 million	$0.12	68.92

Nanovibronix has higher earnings, but lower revenue than Bioventus. Nanovibronix is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nanovibronix and Bioventus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-275.12%	-24.78%	-19.24%
Bioventus	1.39%	26.38%	7.27%

Volatility & Risk

Nanovibronix has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Insider & Institutional Ownership

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 5.2% of Nanovibronix shares are held by insiders. Comparatively, 33.0% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Nanovibronix and Bioventus, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1	0	0	0	1.00
Bioventus	0	1	0	1	3.00

Summary

Bioventus beats Nanovibronix on 9 of the 12 factors compared between the two stocks.

About Nanovibronix

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.